Literature DB >> 25028567

The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity.

Marina Kawaguchi-Suzuki1, Reginald F Frye1, Hao-Jie Zhu1, Bryan J Brinda1, Kenneth D Chavin1, Hilary J Bernstein1, John S Markowitz2.   

Abstract

Milk thistle (Silybum marianum) extracts are widely used as a complementary and alternative treatment of various hepatic conditions and a host of other diseases/disorders. The active constituents of milk thistle supplements are believed to be the flavonolignans contained within the extracts. In vitro studies have suggested that some milk thistle components may significantly inhibit specific cytochrome P450 (P450) enzymes. However, determining the potential for clinically significant drug interactions with milk thistle products has been complicated by inconsistencies between in vitro and in vivo study results. The aim of the present study was to determine the effect of a standardized milk thistle supplement on major P450 drug-metabolizing enzymes after a 14-day exposure period. CYP1A2, CYP2C9, CYP2D6, and CYP3A4/5 activities were measured by simultaneously administering the four probe drugs, caffeine, tolbutamide, dextromethorphan, and midazolam, to nine healthy volunteers before and after exposure to a standardized milk thistle extract given thrice daily for 14 days. The three most abundant falvonolignans found in plasma, following exposure to milk thistle extracts, were silybin A, silybin B, and isosilybin B. The concentrations of these three major constituents were individually measured in study subjects as potential perpetrators. The peak concentrations and areas under the time-concentration curves of the four probe drugs were determined with the milk thistle administration. Exposure to milk thistle extract produced no significant influence on CYP1A2, CYP2C9, CYP2D6, or CYP3A4/5 activities.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25028567      PMCID: PMC4164972          DOI: 10.1124/dmd.114.057232

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  41 in total

1.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

Authors:  M Heim; U A Meyer
Journal:  Lancet       Date:  1990-09-01       Impact factor: 79.321

2.  A Preliminary Study on the Effects of Self-Reported Dietary Caffeine on Pain Experience and Postoperative Analgesia.

Authors:  Nirmani P Karunathilake; Reginald F Frye; Mary F Stavropoulos; Mary A Herman; Barbara A Hastie
Journal:  J Caffeine Res       Date:  2012-12

3.  Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.

Authors:  Sarah J Schrieber; Roy L Hawke; Zhiming Wen; Philip C Smith; K Rajender Reddy; Abdus S Wahed; Steven H Belle; Nezam H Afdhal; Victor J Navarro; Catherine M Meyers; Edward Doo; Michael W Fried
Journal:  Drug Metab Dispos       Date:  2011-08-24       Impact factor: 3.922

4.  In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto.

Authors:  Bill J Gurley; Stephanie F Gardner; Martha A Hubbard; D Keith Williams; W Brooks Gentry; Julie Carrier; Ikhlas A Khan; David J Edwards; Amit Shah
Journal:  Clin Pharmacol Ther       Date:  2004-11       Impact factor: 6.875

5.  Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.

Authors:  Jenny Y Chien; Aroonrut Lucksiri; Charles S Ernest; J Christopher Gorski; Steven A Wrighton; Stephen D Hall
Journal:  Drug Metab Dispos       Date:  2006-04-12       Impact factor: 3.922

6.  The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity.

Authors:  Sarah J Schrieber; Zhiming Wen; Manoli Vourvahis; Philip C Smith; Michael W Fried; Angela D M Kashuba; Roy L Hawke
Journal:  Drug Metab Dispos       Date:  2008-06-19       Impact factor: 3.922

Review 7.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

Authors:  Ulrich M Zanger; Matthias Schwab
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

8.  Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases.

Authors:  Chitra Sridar; Theunis C Goosen; Ute M Kent; J Andrew Williams; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2004-06       Impact factor: 3.922

Review 9.  Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies.

Authors:  David J Kroll; Heather S Shaw; Nicholas H Oberlies
Journal:  Integr Cancer Ther       Date:  2007-06       Impact factor: 3.279

10.  Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities.

Authors:  Roman Zuber; Martin Modrianský; Zdenek Dvorák; Petr Rohovský; Jitka Ulrichová; Vilím Simánek; Pavel Anzenbacher
Journal:  Phytother Res       Date:  2002-11       Impact factor: 6.388

View more
  13 in total

1.  An ex vivo approach to botanical-drug interactions: a proof of concept study.

Authors:  Xinwen Wang; Hao-Jie Zhu; Juliana Munoz; Bill J Gurley; John S Markowitz
Journal:  J Ethnopharmacol       Date:  2015-01-24       Impact factor: 4.360

Review 2.  Pharmacokinetic Interactions between Drugs and Botanical Dietary Supplements.

Authors:  Alyssa A Sprouse; Richard B van Breemen
Journal:  Drug Metab Dispos       Date:  2015-10-05       Impact factor: 3.922

Review 3.  HDI Highlighter, The First Intelligent Tool to Screen the Literature on Herb-Drug Interactions.

Authors:  Anthony Cnudde; Patrick Watrin; Florence Souard
Journal:  Clin Pharmacokinet       Date:  2022-05-31       Impact factor: 5.577

4.  No Clinically Relevant Pharmacokinetic Interactions of a Red Clover Dietary Supplement with Cytochrome P450 Enzymes in Women.

Authors:  Luying Chen; Jaewoo Choi; Scott W Leonard; Suzanne Banuvar; Elena Barengolts; Marlos Viana; Shao-Nong Chen; Guido F Pauli; Judy L Bolton; Richard B van Breemen
Journal:  J Agric Food Chem       Date:  2020-11-16       Impact factor: 5.279

5.  Effect of Low-Furanocoumarin Hybrid Grapefruit Juice Consumption on Midazolam Pharmacokinetics.

Authors:  Marina Kawaguchi-Suzuki; Negar Nasiri-Kenari; Jonathan Shuster; Fred G Gmitter; Paul Cancalon; Felipe de Oliveria; Jennifer Kight; Eileen M Handberg; Carl J Pepine; Reginald F Frye; Rhonda M Cooper-DeHoff
Journal:  J Clin Pharmacol       Date:  2016-09-06       Impact factor: 3.126

6.  Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities.

Authors:  Michael Schink; Oliver Dehus
Journal:  BMC Complement Altern Med       Date:  2017-12-04       Impact factor: 3.659

Review 7.  Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)-Chemistry, Bioavailability, and Metabolism.

Authors:  Michal Bijak
Journal:  Molecules       Date:  2017-11-10       Impact factor: 4.411

Review 8.  Metabolism, Transport and Drug-Drug Interactions of Silymarin.

Authors:  Ying Xie; Dingqi Zhang; Jin Zhang; Jialu Yuan
Journal:  Molecules       Date:  2019-10-14       Impact factor: 4.411

Review 9.  Flavolignans from Silymarin as Nrf2 Bioactivators and Their Therapeutic Applications.

Authors:  Nancy Vargas-Mendoza; Ángel Morales-González; Mauricio Morales-Martínez; Marvin A Soriano-Ursúa; Luis Delgado-Olivares; Eli Mireya Sandoval-Gallegos; Eduardo Madrigal-Bujaidar; Isela Álvarez-González; Eduardo Madrigal-Santillán; José A Morales-Gonzalez
Journal:  Biomedicines       Date:  2020-05-14

Review 10.  Anti-Parkinson Potential of Silymarin: Mechanistic Insight and Therapeutic Standing.

Authors:  Hammad Ullah; Haroon Khan
Journal:  Front Pharmacol       Date:  2018-04-27       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.